Design Therapeutics (DSGN) News
NASDAQ: DSGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
9.02-0.30 (-3.22%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DSGN news summary
We found 3 recent headlines mentioning Design Therapeutics (DSGN): 0 in the past week and 3 in the past 30 days, most often from Nasdaq, Seeking Alpha, GlobeNewswire. For price context, DSGN is down 3.22% at $9.02. The most recent story, "Design Therapeutics, Inc. Reports Third Quarter 2026 Financial Results", was published by Nasdaq on Nov 4, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Design Therapeutics headlines
- Design Therapeutics, Inc. Reports Third Quarter 2026 Financial ResultsDesign Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical programs. The company reported cash, cash equivalents and…NasdaqDSGN, BF.A
- Design Therapeutics GAAP EPS of -$0.32 beats by $0.02Seeking Alpha
- Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business UpdatesDT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027GlobeNewswire